Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to
Risperidone, considered as the reference drug for the treatment of depressive symptoms of
schizophrenia.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation
was changed to XR after consultation with FDA.